In-vitro evaluation of biosynthesized zinc oxide (ZnO) nanoparticles from Cassia glauca against Staphylococcus aureus and Escherichia coli

Zinc oxide nanoparticles were prepared from the Cassia glauca plant and used as antibacterial agents against multiple drug resistance. Staphylococcus aureus and Escherichia coli were isolated from urinary tract infections. Leaf extracts of Cassia glauca demonstrated outstanding promise as lowering agents in the NP creation process. Using UV, FTIR, XRD, DLS, and SEM examination, structural and optical investigations verified the production of effective ZnO NPs. ZnO NPs made from leaf extracts have shown a notable capacity to inhibit numerous drug-resistant S. aureus and E. coli, according to an antibacterial study. The aqueous plant extract was added to the bacteria isolates to inhibit bacterial growth in five various concentrations (0.25, 0.5, 1, 2 and 4) µg/mL, and the results were ineffective on Staphylococcus aureus growth with all concentrations that used in current study, except that E. coli bacterial growth was effect with The aqueous plant extract (ZnO NPs), in concentrations (0.25, 0.5) µg/mL were more effect than other concentrations.The treatment of several infectious diseases in humans can benefit from the manufacture of ZnO NPs utilizing extracts of medicinal plants. Further research will be required to verify these NPs' efficacy in medical applications and their capacity to lessen the risks connected to traditional drugs.